Brief: Nanobiotix Announces Preclinical Data On Improved Delivery, Safety Of LNP-DNA Immunotherapy

Nanobiotix SA

20/04/2026 07:39

April 20 (Reuters) - Nanobiotix SA NANOB.PA:

ANNOUNCES PRECLINICAL DATA SUPPORTING IMPROVED BIOAVAILABILITY AND REDUCED TOXICITY FOR LNP-DNA IMMUNOTHERAPY

PRECLINICAL EVALUATION ASSESSES NANOPRIMER'S POTENTIAL TO OVERCOME RAPID LIVER CLEARANCE FOR LNP THERAPIES

NANOPRIMER PRE-TREATMENT WITH LNP-DNA SHOWS INCREASED BIOAVAILABILITY AND REDUCED TOXICITY

Source text: ID:nGNX4TK0TS

Further company coverage: NANOB.PA

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))